Skip to main content
ACRS $3.48 -0.57%
ACRS logo
ACRS · Aclaris Therapeutics, Inc.
Track ACRS — free
$3.48 -0.02 (-0.57%) Q1 2024 earnings call transcript
Market Cap
$555.14M
Shares
158.61M
Volume · Nov 19 1.89M Avg daily vol (3M) 3.05M
All webcasts

Conference · 2026-11-16

Aclaris Therapeutics, Inc. (ACRS) November 16, 2026 Conference Transcript

Concluded Nov 16, 2026 Audio replay
Nov 16, 2026 23:52 47 turns
Period
2026-11-16
Runtime
23:52
Sources
2 artifacts

Transcript & audio

23:52 Audio
Roger Song Analyst — Jefferies

On to the 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, senior and this covers Smica Biotech. It is my pleasure to have a five-side chat with our company, Clarice Therapeutics. And then we have our CEO, Neil, and then CMO, Jesse. Welcome, gentlemen.

Neil CEO

Thank you. Thank you for having us.

Roger Song Analyst — Jefferies

Awesome. Maybe, Neil, can you just give us a state of art of clarity? You just announced two news this morning. And then where are you now? And then we're heading to why you are excited about that 2027. Thank you.

Neil CEO

Sure. So, yeah, this morning we put out two press releases, one announcing that both Sakatug, which is our T-slip. The monoclonal antibody did not hit the endpoint in atopic dermatitis, and this was a little bit of a flyer for us. We were just testing out. We know that T-slipmab in the past hasn't done well in AD as single-agent therapy, and clearly we've shown with the bispecific that the additive benefit of both is important. And so while disappointing on the clinical front, we did see robust PD responses across the board, particularly on TH1, TH17, and TH2, which was very consistent with the work we did with the bispecific. So that was never in our base case plan moving forward. Our base case plan was to engage in BD on that front. But, yeah, we put that out this morning. In addition, we also announced on the oral small molecule side that we have initiated the 2138 modzatinib study in oral lichen planus that kicked off last week. And so we're excited about that. And so kind of going forward into 27. Oh, and 1 other thing we, we did also a comment on that the next gen that we've been talking about. Uh, we have made it through all of the talks required talks. Now. It's just about pressing the button and filing that this quarter. So that'll be in the coming weeks. Uh, so excited about that both of those oral small molecule programs open up a lot of value coming into 27. so moving forward now. Uh, we have already talked about, uh, in the last couple of weeks, prioritizing as the lead indication for the 05 to by specific. Uh, and then we have the 2138 study up and running and that'll be in all 3 phenotypes of like, and planets, mucosal. Skin and and scalp, uh, and then, of course, advancing the next gen through sad mad work and into in 27.

Roger Song Analyst — Jefferies

Excellent. Okay. As you said, I don't think it's that surprising that this T-slip alone is not specifically working in the AD. Honestly, you're bold enough to run this trial, and then because you have a probably good T-slip monoclonal antibody, maybe my question is how much you learn from that phase two, along with your previous single arm trial, and then how much you learn from that, and then you have a higher or lower confidence for your, by specific using the similar construct of

Neil CEO

Yeah, I still would say it's very high on that front. The 052 data, to me, leveraging the power of the bispecific was unequivocal, and we did take a little bit of a flyer. We did a very small study just to look at the T-slipmab. You know, the original plan was to do a bigger dose-ranging study. I'm glad we didn't, and I think, you know, the fact that it did show activity just didn't quite have the horsepowers kind of makes sense with the disease. If you leave IL-4 and IL-13 untouched to keep inflaming the tissue, then it turns out that perhaps T-slip itself doesn't have enough horsepower to just get it across the finish line. But then when you look at the bispecific construct and you know that IL-4 and 13 are leaving some efficacy on the table, what the T-slip is able to do is just take out the front end of that inflammatory cascade, that amplification loop, and then squash that remaining inflammation. And we certainly saw that in all of the immune proteome work where we normalized the skin proteome with the bispecific, and we're just getting some of this data in, so I'll just comment a little bit on it. We got some O-link data out of the Gutman lab that showed really, really strong biomarker suppression on TH1, TH17, and also on TH2. So I think my conclusion at the end of the day was maybe similar to what a lot of folks thought going in, and I think we definitively answered the question about the single-agent therapy.

Roger Song Analyst — Jefferies

Yeah, okay. Got it. Basically, the drug did what it's supposed to do, but just not really addressing the full spectrum of the A-type dermatitis. That's correct. Okay, I think we can move on from that. And then now we, since we're on that topic, talk about the bispecific, it's T-slip and L4 receptor. We know that's on the opposite side. Tessie just reported positive data in the EOE, and that's probably one of the key reasons you want to go after. Maybe just give us a little bit of biology, so why T-slip could work EOE versus others, I think. GCP works in respiratory disease, but how about the GI? And then why do you think, you know, so far we don't have that many developments in the EOE for the GCP, just because Tensie is the first one going to validate that, or how do you think about the field we're involved from here?

Neil CEO

Yeah, I think maybe I'll start and then Jesse can add in. I think the field is definitely evolving. We've talked to a ton of KOLs over the course of the last two, three months, and there's a pretty clear consensus that EOE is becoming more and more prevalent. In fact, some of these folks are predicting that you'll pretty soon see prevalence over a million patients and basically making some strong statements around following the course of IBD, which is interesting. And as you know, like just historically, folks tried IL-5s, and it turns out that hitting, you know, just the eosinophil itself just isn't enough. And in fact, what we've learned from some of these conversations is when you look at these histo readings, you know, most people just see the EOs per high power field, but what they really are looking at is the entire inflammatory burden. And so that's what these guys track when they look at histo over the course of 52 weeks. And so clearly, you know, T-slip would have an advantage there in terms of hitting some of these inflammatory pathways. And I think since the early days, they've learned that there's a genetic association with T-slip. So there's a lot of great scientific early-stage reasons to believe in that mechanism. And, you know, we know DUPI's approved, and now we have this data that TESI generated, and our molecule kind of reads on both. And maybe, Jesse, if you want to comment additionally.

Jesse Other

Yeah, so absolutely. So the output for the Tezipellumab crossing program was important for us. Going into the Phase 1B readouts, we always had the plan that we were going to be looking at EOE. We were looking at potentially a smaller study, but given the fact that now TSLP is validated in that indication, we feel even more compelled to run a larger study and focus the bispecific program on EOE initially. Yeah.

Neil CEO

And I think, you know, one of the keys that we've learned is also just kind of the slew of, you know, people report out DSQ and they report out EOS per high power field. But on the histo side, what has been flagged as important to us is the complete inflammatory cascade on histology. And that was the problem with Penra, right? All it did was take out the eosinophil. It didn't do anything to all the other inflammatory mediators. Very different with DUPI and TESI. So I think that's an important piece when you think about how does one differentiate on histoscore. And then, you know, the other measures like, you know, DSQ is kind of a blunt object. So there's a lot of other kind of PRO endpoints that are important to the docs and the patient. And I think, you know, depending on who you talk to, whether it's an allergist or a GI doc, endoscopy is critically important. I always kind of wondered before learning about this, if you want to see a response, you look at the skin, right? If you're in dermatology, well, GI doc, you look at the pictures of the esophagus, and that was flagged as a key component. One of the things that has resonated over and over is just speed of response. So what they're not seeing with either of these two agents is kind of a speed component, and they're kind of getting to the same place by week 52. But certainly, you know, we think that's a huge opportunity to differentiate if you have a dual modality approach.

Roger Song Analyst — Jefferies

I see. Okay, so the target profile is you can get to the efficacy a little bit earlier, and then the level of efficacy you are expecting will be comparable or slightly higher. So what's the target profile compared to 10-year-long and then

Neil CEO

10-year-long? Welcome to the call.

Roger Song Analyst — Jefferies

So, O52 is probably the first bispecific during the OT slip-out for doing the EOE, and then any uniqueness, you know, maybe just highlight the uniqueness of O52, so you think you may be better suited than other, you know, bispecific for EOE?

Neil CEO

Well, I think so far, the most direct read-through would be that DoopiWorks, TESIWorks were infinitely more potent than TESI, and we have this bispecific construct and the dosing interval piece. I think with Doopi administered, you know, at least on label, QWeekly is an issue. And so I think roping that into the program, testing out the longer dosing intervals will be important. And we anticipate doing an induction and kind of maintenance kind of construct. Okay.

Roger Song Analyst — Jefferies

Got it. Okay. All right. And then you are going to run the phase two next year. So what's the current thinking about the design? You know, as you said earlier, different ways to measure the benefit of the disease and there may be a bispecific can have a different benefit. So just give us a little bit of high level thoughts of the design.

Jesse Other

Yeah, so absolutely. We think that this initial study with the bispecific in EOE will be important to capture the broad-spectrum response. We're going to be looking at histologic outcome measures, we're going to be looking at symptom outcome measures, and then we're also going to be looking at endoscopic outcome measures. And we think it's the total package that we'll be evaluating with regards to endpoints for this initial EOE study. The goal for the study will be to run an efficient design, meaning moving from the phase two to the registrational portion as rapidly as possible, and the design will reflect that speed.

Roger Song Analyst — Jefferies

Okay, got it. And then I remember when you, you know, Prioritize the EOE, you are thinking about second indication. Now, with the, what's that, this data, you know, how we think about, are you still committed to the second indication, or you want to serve the reserves and capital for other programs?

Neil CEO

So we're going to guide to that before the end of the year, and we'll continue to. The other two 1B studies are still ongoing, and then we're still sifting through some of the BOSA work itself. But, you know, I don't, although I wanted the BOSA to be stat-sig, I'm not surprised by it, so I don't think it has that much of an influence. The two studies are testing different concepts, and we'll provide further guidance on that before the end of the year.

Roger Song Analyst — Jefferies

Is that the truth between the asthma and the atopidomatitis or something else beyond those three indications?

Neil CEO

I think it's really between those two, and I think one of the things we're thinking about is doing a study design in one of the two that perhaps incorporates a positive control so that you are more definitive or maybe taking dupy failures in. You know, something akin to a little bit what Pfizer's thinking about. I think it's becoming increasingly difficult to do these cross-trial comparisons on such disparate data sets. As we've talked about extensively, our 052 study in AD encompass very, very severe patients, which is quite different in why I was so, you know, happy with that result. But, you know, perhaps if you're not in the derm field, it's not fully appreciated, right? And so, you know, the only other way to kind of definitively show something is do either a prior single therapy failure study or do a positive control.

Roger Song Analyst — Jefferies

Okay. Basically, you want to choose one indication among those two with some, you know, design to show the benefit. Okay. Got it. All right. Right. And then I think a lot of investors really focus on your ITK Jax3 for Lichen Planus for the right reason. And maybe just remind us the study design, and then also specifically how you power for ODSS at a 16-week interim.

Neil CEO

All right. Do you want to talk about the design?

Jesse Other

Yeah, absolutely. So we're really excited about this Lichen Planus syndication, and we're getting a lot of enthusiasm from investigators as well as patients as we're speaking about it. So the design is a basket cohort design, and the reason we call it a basket design is there'll be multiple subtypes. So the main subtypes that will be included are the mucosal, the cutaneous, and then the scalp form, which is the lichen planil pilaris. We're also taking it in a cohort by cohort fashion. The initial cohort will be the oral component, and then we'll move subsequently to the cutaneous and the LPP. The primary endpoint for the clinical study will be ODSS. So ODSS is the oral disease severity score originally developed for oral pemphigoid, subsequently adapted and validated in oral lichen planus. We have a 16-week endpoint. The goal is to enroll somewhere between 35 and 40 patients. With an interim analysis after about 60% of patients have reached the week 16 endpoint. We're also going to be including the IGA score because there is some interest potentially from a regulatory perspective that IGA may become the default endpoint in that. So we want to understand what the power and will look like for the phase three study. We'll also be looking at patient reported outcomes as well. But great news to now be able to say and to announce that we've initiated that study, and we're really looking forward to progressing through that clinical study next year.

Roger Song Analyst — Jefferies

Got it. And then at intern, as you said, you have a certified 2040 patient, they will look at the ODSS. First of all, how many endpoints you will look at at the intern for those subgroups of the patient? And then the two is, you're going to see some statistics from that intern given the smaller sympathize.

Jesse Other

Yeah, so absolutely. So for the initial interim, we'll be looking at all of the relevant endpoints, including ODSS, IGA, as well as the patient-reported outcomes. The study is powered, and we've powered it based on ODSS. We'll communicate further what exactly the expectations are. The reason we like ODSS is it's a continuous outcome measure. It goes from 0 to 106, meaning it's very sensitive to change, which means we were able to power the study with a fairly reasonable sample size for the initial cohort.

Roger Song Analyst — Jefferies

Got it. And then you say powered because it is phase two. It's not like you have some alpha penalty at the interim. It's power is 0.05 or 0.1. And what kind of power are you thinking?

Jesse Other

Yeah, so we're looking at it from the perspective of a reasonable powered study for that size. ODSS, again, as I mentioned, is that continuous variable, very sensitive to change, and we're able to power the study on a very small number of subjects.

Roger Song Analyst — Jefferies

Okay. And then I believe your goal is to report the intern and talk with the FDA, potentially can expand that into the pivotal. You say you will guide the expectation later, but just what will be sufficient data for FDA to allow you to expand to the pivotal?

Jesse Other

Yeah, no, it's a great question. And so we were very interested in pursuing this path, and we were very happy to see the engagement from the FDA with the FastTrack designation. I think what that allows us is additional interaction with the agency moving forward. So the plan would be once we have the interim analysis data in hand is to go back to the agency and discuss what the registrational program will look like.

Neil CEO

Yeah, I think whenever you have an indication like this, where patients are suffering with moderate to severe disease, I mean, you think about having canker sores all over your mind. I mean, it's pretty distressing. The fact that we got fast-track designation for this allows us this flexibility and opportunity. So, and we think, you know, look, if you just look at the literature, we think we're going to see responses quite a bit earlier than week 16. So it'll always be the kind of aggregate of the efficacy and safety data to push to the next level. But we're quite confident in being able to do that.

Jesse Other

Yeah.

Roger Song Analyst — Jefferies

Okay. And then we know we don't have approved the drug yet, but also maybe some of the other, you know, Jack also want to do this similar kind of indication. So how do we think about, you know, on one side of the clinically meaningful benefit, also competitively, how you think, you know, can do?

Neil CEO

So, yeah, so there's not like a great amount of double-blind placebo-controlled data out there. Obviously, a lot of good case reports, things like that. You know, I think, you know, when you think about mechanistic match, that's when we get really excited because LP is driven through an anginic stimulation of the T cell receptor. The only way to take that out is to hit upstream at the ITK level, just like cyclosporine might do. And so mechanistically, there's just not another compound out there that has the same value prop, right? So I think we feel good about that component. And in terms of just, you know, what we feel is a reasonable kind of table stakes, you know, when you look at ODSS, if you're seeing like something like a 50% response, I think that would be pretty compelling. You're very unlikely in these sorts of patients at the moderate to severe end of the spectrum with particular mucosal. This is not a waxing or waning disease. This is a disease that kind of comes and smolders for years and years and years. So I think that gives us a pretty good feeling going in.

Roger Song Analyst — Jefferies

How much is the placebo effect we should expect? Because there's small sample size, you know, when we look at it.

Neil CEO

Yeah, I mean, there are… I can't really give you a great answer because there hasn't been a ton of work done in this area. There has been a recent study that was just published using a topical corticosteroid versus placebo. The caveat is they did this in patients with very mild disease, but even with that, it was, I think, a 20% response rate. So even at the mild end of the spectrum, exceedingly low just by, if I compare to AD, you know, and so that, and they were able to generate a nice spread with a small number of patients just with that. So, and again, that's why we're choosing kind of the IGA3s and 4s because you don't want to, you know, that's in stark contrast to cutaneous. As an example, cutaneous tends to wax and wane over time. It's a little bit more unpredictable than mucosal.

Jesse Other

Got it.

Roger Song Analyst — Jefferies

And then you say 20% is the ODSS.

Neil CEO

Correct. Yep.

Roger Song Analyst — Jefferies

All right. And then, by the way, that trial is also topical at the placebo?

Neil CEO

Yeah, that was topical, and it was much milder. Yeah. So they had, comparatively, they had ODS scores at baseline that were much lower. Got it. But that was just published, like, what, a week ago?

Roger Song Analyst — Jefferies

Exactly. Yeah, just very recently.

Neil CEO

Yeah.

Roger Song Analyst — Jefferies

Got it. You know, LP did not have any approved drug, and then your ITK also hit a JAG-3. And then I believe in the past, talking about atopic dermatitis, you think maybe the base case, you're going to have a bad box and a box warning, just like all the JAG. So how do you think about the LP, how likely you will get the bad box and how likely you will remove? And then for this indication, you think it will be acceptable?

Neil CEO

Yeah, I mean, I always have to go with a conservative base case, right, because you're not going to get that answer until review time. You know, I do think that over the course of the years since the TOFA data, and if you just look with a very keen eye at the labels of a lot of these drugs, they're all a little bit different. Not every black box is the same. I don't worry too much about that in the context of this indication. Nothing's approved. You know, right now we're treating these patients with things like cyclosporine, prednisone, Plaquenil, which, you know, has, and people forget this, like Plaquenil has retinal toxicity and liver issues and all sorts of bad things. So I think there's, you know, if you catch a black box that has a warning or a risk about infection, I think you would count yourself lucky in that regard.

Roger Song Analyst — Jefferies

Got it. Okay, so just lastly, you also are advancing your selective ITK program, so 9494. So where's the timeline look like? And then, because it is hitting high, you know, just upstream, as you said, the ITK, what's the indication selection, and then what's the development plan going to look like?

Neil CEO

So, we're looking at TH2-based indications, and we're really thrilled that, you know, we've checked all the boxes on the tox front and looking forward to filing that in the coming weeks. And, you know, the next step would be the SAD-MAD work, and we'll try to incorporate some patients in the MAD work that have some disease, perhaps some elevated phenol levels where we can pick up some early looks. And then we advance to POC. So I think the indications, we haven't totally decided on those yet, but they would be TH2-based and looking at things like atopic or asthma. As an oral.

Roger Song Analyst — Jefferies

Got it. It's a TH2 or TH1? You say earlier, you say TH1. TH2. TH2. Okay, got it. All right. I think the time's up. And thank you so much, everyone. And thank you, Neil and Jesse. Thank you.

Analyst Q&A · 1 question
Full-screen source Call document